Literature DB >> 17211770

[Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders].

Hans-Bernd Rothenhäusler1.   

Abstract

Since the acquired immune deficiency syndrome (AIDS) was first recognized in 1981, more than 25 million individuals have died from complications of the human immunodeficiency virus (HIV) infection. The introduction of highly active antiretroviral therapy (HAART) in 1995 has resulted in a significantly decreased incidence rate of AIDS in the developed world. As HAART led to considerable improvements in survival for patients with HIV infection, HIV-neurotropically associated neuropsychiatric disorders have become an increasingly important challenge for clinical medicine. This article gives an overview of epidemiology, clinical features, diagnosis, and therapy of HIV-induced cognitive-motor impairments including HIV-associated dementia complex, organic mood disorders and psychosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17211770     DOI: 10.1007/s10354-006-0353-y

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  78 in total

1.  Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.

Authors:  N Sacktor; G Schifitto; M P McDermott; K Marder; J C McArthur; K Kieburtz
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

2.  Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial.

Authors:  J G Rabkin; G J Wagner; R Rabkin
Journal:  Am J Psychiatry       Date:  1999-01       Impact factor: 18.112

3.  [Status of HIV-infections 2005].

Authors:  Anja Potthoff; Norbert H Brockmeyer
Journal:  Herz       Date:  2005-09       Impact factor: 1.443

Review 4.  Severe mental illness and HIV-related medical and neuropsychiatric sequelae.

Authors:  J S McDaniel; D W Purcell; E W Farber
Journal:  Clin Psychol Rev       Date:  1997

Review 5.  Antiretroviral therapy-induced psychosis: case report and brief review of the literature.

Authors:  R Foster; D Olajide; I P Everall
Journal:  HIV Med       Date:  2003-04       Impact factor: 3.180

6.  Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients.

Authors:  A J Elliott; K K Uldall; K Bergam; J Russo; K Claypoole; P P Roy-Byrne
Journal:  Am J Psychiatry       Date:  1998-03       Impact factor: 18.112

7.  Expression of HIV regulatory and structural mRNA in the central nervous system.

Authors:  C A Wiley; M Baldwin; C L Achim
Journal:  AIDS       Date:  1996-07       Impact factor: 4.177

Review 8.  The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex.

Authors:  R W Price; B Brew; J Sidtis; M Rosenblum; A C Scheck; P Cleary
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

Review 9.  Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era.

Authors:  Christian Manzardo; María Del Mar Ortega; Omar Sued; Felipe García; Asunción Moreno; José M Miró
Journal:  J Neurovirol       Date:  2005       Impact factor: 2.643

Review 10.  Psychiatric complications in human immunodeficiency virus infection.

Authors:  E Koutsilieri; C Scheller; S Sopper; V ter Meulen; P Riederer
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

View more
  1 in total

1.  [Emotional status, cognitive performance and quality of life in HIV-infected patients. Results of an exploratory study].

Authors:  D Baumschlager; A Haas-Krammer; H-B Rothenhäusler
Journal:  Nervenarzt       Date:  2011-07       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.